ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0611

Disease Activity and Disability Are Not Associated with Rehabilitation Utilization in African Americans with Rheumatoid Arthritis
Abstract Number: 1295

Disease Activity and Mental Health in SLE Patients: A Cross-section Study with Self-Assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
Abstract Number: 1319

Disease Activity and Mental Health of as Patients: A Cross-section Study with Self-assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
Abstract Number: 0405

Disease Activity and Quality-of-Life Outcomes in Patients with Behçet’s Syndrome Who Achieved and Maintained Oral Ulcer Complete Response with Apremilast Treatment
Abstract Number: 1884

Disease Activity in an Axial Spondyloarthritis Cohort During the COVID-19 Pandemic
Abstract Number: 1714

Disease Activity Trajectories for Early and Established Rheumatoid Arthritis: Real World Results from a Rheumatoid Arthritis Cohort
Abstract Number: 0674

Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan
Abstract Number: 2041

Disease Features of Systemic Sclerosis Are Associated with Alterations in Gastrointestinal Microbial Composition in Two Independent Cohorts
Abstract Number: 1764

Disease Modifying Anti-rheumatic Drug and Biologic Therapy in Pregnancy: A Single-center Mixed Methods Study
Abstract Number: 1014

Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years
Abstract Number: 1401

Disease Mutation That Weakens ZAP70 Autoinhibition Enhances Responses to Weak and Self Ligands
Abstract Number: 0448

Disease-related factors associated to atherosclerotic disease in axial spondyloarthritis. A mutlicenter study with 806 patients.
Abstract Number: 0442

Disparities in CoronaViridae Infection Are Readily Apparent in Rheumatology Patients Despite Use of Hydroxychloquine And/or Methotrexate
Abstract Number: 0049

Disparities in Patient Portal Use Among Patients with Rheumatic and Musculoskeletal Diseases in a Large Academic Medical Center
Abstract Number: 0035

Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].